The cardiovascular and platelet effects of epoprostenol (prostacyclin, PGI2) are unaffected by beta-adrenoceptor blockade in man
- PMID: 6127095
- PMCID: PMC1427645
- DOI: 10.1111/j.1365-2125.1982.tb01993.x
The cardiovascular and platelet effects of epoprostenol (prostacyclin, PGI2) are unaffected by beta-adrenoceptor blockade in man
Abstract
1 Atenolol 0.2 mg/kg i.v., propranolol 0.2 mg/kg i.v. or placebo were given in a double-blind crossover study to six healthy male subjects, and the effects of a subsequent infusion of epoprostenol (prostacyclin, PGI2) 0-6 ng kg-1 min-1 monitored. 2 PGI2 caused a tachycardia, a fall in diastolic blood pressure, a rise in pulse pressure, reduction in pre-ejection period (PEP) and rise in left ventricular ejection time index (LVETI), headache and facial flushing at doses of PGI2 greater than 2 ng kg-1 min-1,, (P less than 0.05). 3 Beta-adrenoceptor blockade did not prevent the tachycardia in response to PGI2, and did not interact with any of the other dynamic effects of PGI2. 4 In vitro, PGI2 at 1 and 2 ng/ml inhibited platelet aggregation to ADP (P less than 0.01), although no significant effect on platelet aggregation was seen in the in vivo study. Atenolol and propranolol at a final concentration of 1 microgram/ml did not affect this in vitro study. Atenolol and propranolol at a final concentration of 1 microgram/ml did not affect in vitro effect of PGI2 on platelet aggregation. 5 Pretreatment with atropine 0.04 mg/kg i.v. in three subjects did not attenuate the tachycardia caused by PGI2 infusion, even though the baseline heart rate was increased. 6 Adverse effects to PGI2 infusion included sudden bradycardia, pallor and sweating, suggesting that the Bezold-Jarisch reflex seen in animals in response to PGI2 may also occur in humans. 7 Neither increased sympathetic drive nor vagal withdrawal are likely causes of the tachycardia following PGI2 infusion.
Similar articles
-
Effects of intravenous epoprostenol on platelets and the cardiovascular system are not potentiated by dipyridamole.Clin Pharmacol Ther. 1983 Feb;33(2):178-82. doi: 10.1038/clpt.1983.27. Clin Pharmacol Ther. 1983. PMID: 6337004 Clinical Trial.
-
Noninvasive assessment of the cardiovascular effects of prostacyclin (PGI2) in man.Eur J Cardiol. 1980;12(2):73-80. Eur J Cardiol. 1980. PMID: 7002563 Clinical Trial.
-
Effects of intravenous infusion of prostacyclin (PGI2) in man.Prostaglandins. 1980 Feb;19(2):319-32. doi: 10.1016/0090-6980(80)90030-1. Prostaglandins. 1980. PMID: 6992228
-
Platelet actions of stable carbocyclic analogues of prostacyclin.Circulation. 1985 Dec;72(6):1219-25. doi: 10.1161/01.cir.72.6.1219. Circulation. 1985. PMID: 3905049 Review. No abstract available.
-
Effects of PGI2 and its stable analog on platelet function in hyperlipoproteinemia.Pharmacol Res Commun. 1988 Sep;20 Suppl 3:85-99. doi: 10.1016/s0031-6989(88)80108-5. Pharmacol Res Commun. 1988. PMID: 2465554 Review. No abstract available.
Cited by
-
Systolic time intervals: a review of the method in the non-invasive investigation of cardiac function in health, disease and clinical pharmacology.Postgrad Med J. 1983 Jul;59(693):423-34. doi: 10.1136/pgmj.59.693.423. Postgrad Med J. 1983. PMID: 6353394 Free PMC article. Review.
-
The effect of a prostaglandin DP-receptor partial agonist (192C86) on platelet aggregation and the cardiovascular system in healthy volunteers.Br J Clin Pharmacol. 1992 Oct;34(4):344-51. doi: 10.1111/j.1365-2125.1992.tb05641.x. Br J Clin Pharmacol. 1992. PMID: 1457268 Free PMC article.
-
The cardiovascular and platelet actions of 9 beta-methyl carbacyclin (ciprostene), a chemically stable analogue of prostacyclin, in the dog and monkey.Br J Pharmacol. 1985 Jun;85(2):547-55. doi: 10.1111/j.1476-5381.1985.tb08892.x. Br J Pharmacol. 1985. PMID: 3896365 Free PMC article.
-
A chemically stable analogue, 9 beta-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man.Br J Clin Pharmacol. 1984 Dec;18(6):921-33. doi: 10.1111/j.1365-2125.1984.tb02565.x. Br J Clin Pharmacol. 1984. PMID: 6085004 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous